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This case study examines the automation and process change
options available to emerging discovery/development stage phar-
maceutical companies when considering implementing sophisticated
high-throughput screens. Generally there are both ￿nancial and
personnel constraints that have to be addressed when implementing
state-of-the-art screening technology in smaller companies which
generally are not as signi￿cant as in large pharmaceutical com-
panies. When NPS Pharmaceuticals considered installing a
Molecular Devices FLIPR
TM for high-throughput cell based
screening it became clear that, to make the best decision, the whole
screening process at NPS Pharmaceuticals from screen develop-
ment and validation, tissue culture, compound distribution, data
handling and screening had to be re-examined to see what
automation options were possible and which, if any, made sense
to implement. Large scale automated systems were not considered
due to their cost and the lack of in-house engineering infrastructure
to support such systems. The current trend towards workstation
based laboratory automation suggested that a minimalist approach
to laboratory automation, coupled with improved understanding of
the physical process of screening, would yield the best approach.
Better understanding of the work ￿ow within the Biomolecular
Screening team enabled the group to optimize the process and decide
what support equipment was needed. To install the FLIPR
TM,
train users, set up the tissue culture protocols for cell supply,
establish high-throughput screening database protocols, integrate
compound distribution and re-supply and validate the pharmacol-
ogy on four cell based screens took the team 3 months. The
integration of the screening team at the primary, secondary and
tertiary screening stages of the target discovery project teams at
NPS has enabled us to incorporate minimal automation into the
Biomolecular Screening Group whilst retaining an enriching work
environment. This is re￿ected in our current consistent throughput
of 64 96-well microplates per day on the FLIPR
TM, a ￿gure that
is comparable with that achieved within most major pharmaceu-
tical companies. This case study suggests that process optimization
coupled with modern stand alone automated workstations can
achieve signi￿cant throughput in a resource constrained environ-
ment. Signi￿cantly greater throughput could be achieved by coup-
ling the process improvement techniques described above with
384-well microplate technology.
Introduction
High-throughput screens at NPS Pharmaceuticals in-
clude cell based assays that are designed to discover
agonists and antagonists of G-protein coupled receptors
(GPCRs). They are based on the ability to measure
intracellular calcium concentration changes as a result
of the secondary signalling responses of these GPCRs to
test substances. The response is monitored through
¯ uorescent changes of the intracellular dye Fluo-3 as a
response to changing calcium concentration.
Experimental
Historically, the equipment used was an 8-channel
¯ uorometer with integrated liquid handling, capable of
reading one column (eight wells) of a 96-well microplate
every 5 minutes. This equipment was constructed in-
house from commercially available components, and
consisted of a Hamilton MPH2200 8-probe liquid hand-
ler (Hamilton Co., Reno, NV), an X± Y stage to move
the microplate across the deck of the liquid handler, and
an 8-light pipe ® bre optic bundle underneath the micro-
plate to provide light paths for both the excitation light
and to feed the emission light to a single photomultiplier
tube (PMT) multiplexed to the 8-® bre optic bundle
using a rotating scanning mirror. The photomultiplier
signal was detected by a signal processing unit, the
output of which was digitized and stored in a computer.
All the control software for the X± Y stage and the motor
controlling the mirror scanning the PMT were written
in-house and these motors were controlled by a PC
responsible for digitizing and collecting the signal data.
A separate PC with a handshake via an I/O port
controlled the Hamilton liquid handler and initiated
the liquid handling operations. All the equipment was
contained within a darkroom to exclude ambient light
from the test plate. Typically the time for analysing a 96-
well microplate was about 60 minutes.
After purchase of the FLIPR
TM from Molecular Devices,
the equipment con® guration for the assay consisted of the
FLIPR
TM I (Molecular Devices, Sunnyvale CA), a
Skatron model 301 ScanWash/ScanStack plate washer
(Molecular Devices, Sunnyvale, CA), a Hamilton
MPH2200 16 probe liquid handler (Hamilton Co.,
Reno, NV) and a Forma model 310 tissue culture
incubator (Forma Scienti® c/Savant Instruments, Mar-
ietta, OH). All these units were contained in ambient
laboratory conditions (no darkroom). Typically the time
to analyze a 96-well microplate was about 5 minutes.
Bioinformatics was handled by ActivityBase (ID Business
Solutions, Emeryville,CA).
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1 week before assay:
plate out HEK-293 cells containing the human cal-
cium receptor, grow at 378C for 7 days, replacing
medium every day.
On the day of assay:
. Cell loading:
(1) add bu￿ er containing Fluo-3 to the microplate,
(2) incubate microplate in the dark for 60 minutes,
(3) remove loading bu￿ er,
(4) add test bu￿ er.
. Test compound plate preparation:
(1) whilst cell assay plate is being loaded with
¯ uorophore, place microplate on Hamilton
liquid handler,
(2) initiate addition of bu￿ er from reservoir on
Hamilton,
(3) mix bu￿ er in test plate wells, washing between
additions.
. Assay:
(1) place microplate containing cells loaded with
dye on X± Y stage on Hamilton,
(2) initiate start sequence on system (built in 15
second delay),
(3) exit darkroom and close door,
(4) repeat after microplate run is completed.
Process ￿ow with FLIPR
TM I system
24 hour prior to assay:
(1) plate cells at validated density from ¯ asks,
(2) grow overnight at 378C in tissue culture area,
(3) transfer assay ¯ asks to screening tissue culture
incubator.
On the day of assay:
. Test compound plate preparation:
(1) load 16 plates on to 16-probe Hamilton liquid
handler,
(2) load bu￿ er reservoirs,
(3) initiate Hamilton addition program,
(4) repeat four times.
. Cell loading:
(1) load ® rst plate with Fluo-3,
(2) put in dark area,
(3) 5 minutes later, load second plate with Fluo-3,
(4) put in dark area,
(5) repeat every 5 minutes for total plate run on
that day,
(6) after 30 minutes, remove 1st plate,
(7) put plate on Skatron washer,
(8) run Skatron washer to wash o￿ loading bu￿ er
and to add ® nal test bu￿ er,
(9) repeat every 5 minutes.
. FLIPR
TM assay:
(1) open tip loading hatch,
(2) load new set of tips,
(3) open FLIPR
TM microplate drawer,
(4) place assay plate in centre location of FLIPR
TM
loading tray.
(5) place compound plate in right hand location in
FLIPR
TM loading tray,
(6) place challenge plate in left hand location in
FLIPR
TM loading tray,
(7) shut FLIPR
TM microplate drawer,
(8) open new data ® le,
(9) initiate test sequence,
(10) shut data ® le.
Process ￿ow for secondary and tertiary assays:
(1) Cuvette-based. Prepare bu￿ ers, load cells, put in
single cuvette ¯ uorimeter, add test compound,
measure response, 5 minute assay. Automated
data capture of curve, manual curve analysis.
Repeat for next concentration of agonist, an-
tagonist. Throughput was limited. 25 com-
pounds with an 8 point concentration curve
required 6 days of testing and 30 hours of
machine time.
(2) FLIPR
TM microplate based. 8 point curve run on
25 compounds. Preparation, loading, testing 1
day, 30 minutes of machine time.
Results and discussion
The results for the productivity and reduction in waste in
the Tissue Culture Group were remarkable. E￿ ort ex-
pended in validating correct plating densities, expansion
of cells in tissue culture ¯ asks instead of microplates and
plating cells on demand 24 hours before the assay
resulted in a reduction of wasted plates from about
50% of plates with the old process and instruments to
less than 5% of plates. At a throughput of 64 plates per
day, over a 4 month period this potentially saved about
10000 plates from being wasted, about a $50000 saving
in materials cost, not counting downtime. This also
allowed greater ¯ exibility in assay schedule, since cells
could be maintained in tissue culture ¯ asks up to24 hours
prior to the assay when a commitment to the cell line for
the next day would be made. If priorities changed, then
cell lines could be switched with about 24 hours notice,
impossible if a one week long cell growth cycle in
microplates had continued.
The results on the throughput of the assay was also
remarkable. Prior to the installation of the FLIPR
TM,
throughput was limited to about two runs of eight plates
per day. Even though this increased slightly when the
second home built machine was operational, continued
problems with maintaining the unit operational never
achieved the expected productivity gains. Installation of
the FLIPR
TM when fully operational resulted in four test
cell lines and the control wild type cell line being run per
week, a total throughput of 320 plates per week, a 20-fold
improvement. This was maintained for the 5± 6 month
operation of the unit for these screens.
The major problems encountered in attempting to up-
grade the in-house 8-channel ¯ uorometers included ma-
chine serving di￿ culties, lack of in-house engineering
expertise, space requirements, obsolete and unobtainable
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machines, lack of reproducibility in obtaining data be-
tween machines, unreliability of the 16-probe upgrade to
one machines and requirements for a separate darkroom
for each machine.
After the problems encountered in attempting to upgrade
the in-house ¯ uorometer systems became extreme, we
evaluated the FLIPR
TM I at Molecular Devices’ facilities
in Sunnyvale. These tests, which were conducted over
two days, convinced us that replacement of the in-house
systems with a FLIPR
TM I would be the most cost
e￿ ective solution because the results were reproducible,
the limit of detection of response was lower, the quality of
the data was better and the throughput potential was
high. A purchase decision was made in June 1998, the
machine was delivered and installed by mid-July and
training of the users completed by the end of July 1998.
This included the time necessary to make mechanical
changes to the room and to establish new electrical and
cooling water services for the FLIPR
TM.
During this period we developed new process protocols to
allow operation for four out of ® ve days per week.
Included in this process was an evaluation of what
automation or robotic systems should be implemented.
Constraining our decision was the realization that we
were dealing with a cell based system that required dye
loading and maintenance of physiological conditions
throughout the assay. Together with the non-robotic
friendliness of the FLIPR
TM I system, a lack of in-house
engineering support and a need to have the system fully
operational as quickly as possible made us decide not to
integrate the FLIPR
TM I into a robotic system. We did
decide to use existing liquid handling workstations to
handle plate preparation tasks, and purchased a Skatron
plate washer to make the dye loading and microplate
washing steps more e￿ ective. The plate transfer steps
were done manually. We started at relatively low
throughput, and gradually increased plate throughput,
with the operators ® nally feeling comfortable at 64 plates
per day. One method used to achieve this throughput
was to use two operators per day, one assisting in bu￿ er
and test plate preparation and the other running the
FLIPR
TM.
Screen validation began at the end of July 1998 and we
were running 32 plates per day by the end of November
1998, with bioinformatics protocols in place. By the end
of December 1998 we had increased throughput to 48
plates per day and had started writing the secondary and
tertiary screening protocols. By the end of February 1999
we had ® ve screens running at 64 plates per day, with all
bioinformatics protocolsoperating. Usually we double up
on screens on one day per week, so the daily throughput
achieved here was in fact 128 plates per day or 10000
samples per day. By the end of August 1999 all ® ve
screens had ® nished the entire NPS compound deck.
Although it is easy to quantify the throughput of the
assay, and identify a productivity improvement of 12± 20-
fold, this was achieved only by integrating the work¯ ow
of the screening, tissue culture, bioinformatics and com-
pound distribution groups. During the initial screen
validation period, three essential processes took place.
The ® rst of these was the establishment of tissue culture
protocols for the growth of the recombinant cell lines in
both ¯ asks and microplates. One important parameter
that was established through experimentation was the
plating density required for a viable assay in the
FLIPR
TM. Once this was established the plating density
required at 24 hours prior to assay was established, and
from this was derived the number of T-125 ¯ asks and
seeding/splitting strategy needed to provide the total
number of cells to plate 64 microplates for next-day
screening. The second of the processes was the establish-
ment of a database protocol for the primary screening
assay. The protocol for the ® rst screen took the longest.
Protocols for later screens were essentially copy, cut and
paste operations from this initial screen protocol. The
® rst protocol was written in parallel with the develop-
ment of the corresponding cell line tissue culture proto-
cols, and so was ready when screening was initiated. The
third process was the validation of the pharmacology of
the screen and the assay conditions. Variables that were
optimized included dye loading times and dye concen-
tration, the bu￿ er type and composition, addition or not
of dye leakage inhibitors and controls and standards and
their concentration on the microplate.
Another measure of productivity gain is shown by in-
dication that 7 to 10 FTEs were used in June 1997 for
primary, secondary and tertiary screening with the old
in-house rigs and, in comparison, after March 1999, only
4 FTEs were needed for the same or greater amount of
screening in the primary, secondary and tertiary phases.
There were other bene® ts from the FLIPR
TM based assay
with limited automation. The instrument itself was al-
ways accessible manually and not integrated as part of a
large automated system. This made it easy for small runs
of plates during screen development to be accommo-
dated. Also the increased data output enabled responses
to medicinal chemistry SAR to be made more rapidly by
the screening group for the project team. In addition, the
assays run each day on the machine could be scheduled
more ¯ exibly, improving response time to project needs
and demands.
These process and hardware changes have reduced
waste, decreased downtime and ultimately have de-
creased the cost per compound screened. This was ac-
complished with minimal costÐ two new stand alone
workstations (the FLIPR
TM and the Skatron plate
washer). Savings were achieved by reuse of the Hamilton
liquid handlers that were part of the old in-house screen-
ing rigs as compound plate preparation units.
Summary
Before making a commitment to a large scale tightly
integrated system, smaller companies need to consider
the need for rapid screen implementation, the availability
of core engineering resources and capital costs as key
issues. It may be that alternative process improvement
steps that can be done at no cost and use loosely
integrated automated workstations as alternatives pro-
vide a more ¯ exible solution to throughput improve-
ments. As in the case of NPS’s cell based assays,
throughput comparable to or exceeding that attainable
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and ® nancial resources was achieved in a sustainable
manner. A whole compound deck of 100000 compounds
could be screened within 6 weeks using the processes and
systems described here. As plate densities increase from
96-well to 384-well plates for FLIPR
TM type cell based
assays, use of the FLIPR
TM II in a similar minimally
automated system could yield throughputs at the thresh-
old of 100000 samples/week in cell based functional
assays.
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